AC Immune (ACIU) Projected to Announce Quarterly Earnings on Tuesday

AC Immune (NASDAQ:ACIU) is expected to issue its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect AC Immune to post earnings of $0.0981 per share and revenue of $34.0840 million for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 12:30 PM ET.

AC Immune (NASDAQ:ACIU) last posted its quarterly earnings results on Thursday, April 30th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.01. AC Immune had a negative return on equity of 125.26% and a negative net margin of 1,788.02%.The business had revenue of $1.40 million for the quarter, compared to the consensus estimate of $0.33 million. On average, analysts expect AC Immune to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

AC Immune Stock Down 1.1%

Shares of ACIU traded down $0.03 during midday trading on Tuesday, reaching $2.27. 27,320 shares of the stock were exchanged, compared to its average volume of 297,137. The company has a market capitalization of $231.42 million, a P/E ratio of -2.77 and a beta of 1.57. The company has a current ratio of 0.87, a quick ratio of 1.02 and a debt-to-equity ratio of 0.11. AC Immune has a 52 week low of $2.03 and a 52 week high of $4.00. The company’s 50 day moving average is $2.46 and its two-hundred day moving average is $2.84.

Insider Buying and Selling

In other AC Immune news, CEO Andrea Pfeifer sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $2.79, for a total value of $27,900.00. Following the completion of the sale, the chief executive officer directly owned 3,820,288 shares in the company, valued at $10,658,603.52. This trade represents a 0.26% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 4.60% of the stock is owned by insiders.

Hedge Funds Weigh In On AC Immune

A number of large investors have recently made changes to their positions in ACIU. Goldman Sachs Group Inc. increased its position in shares of AC Immune by 46.9% during the fourth quarter. Goldman Sachs Group Inc. now owns 18,555 shares of the company’s stock worth $58,000 after purchasing an additional 5,920 shares in the last quarter. EFG International AG acquired a new stake in shares of AC Immune in the 4th quarter worth $41,000. Private Advisor Group LLC purchased a new position in AC Immune during the 3rd quarter worth $48,000. Susquehanna International Group LLP purchased a new position in AC Immune during the 3rd quarter worth $63,000. Finally, Sei Investments Co. acquired a new position in AC Immune during the 2nd quarter valued at about $51,000. 51.36% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ACIU has been the subject of a number of research reports. HC Wainwright reaffirmed a “buy” rating on shares of AC Immune in a research note on Wednesday, July 1st. Weiss Ratings lowered shares of AC Immune from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 8th. Finally, BTIG Research reissued a “buy” rating and issued a $8.00 price objective on shares of AC Immune in a research note on Monday, May 4th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $7.50.

AC Immune Company Profile

AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.

Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.